Cancer Biomarkers Market to Reach $15,737 Million, Globally, by 2022


quote Cancer biomarkers market growth is attributed to the rise in concern for targeted cancer therapies coupled with better companion diagnostic tests for cancer. In many cases, biomarker tests confirm the existence of diseases that can be treated at an early progression stage. In others, the biomarkers can act as a “surrogate end point” which would help to decide whether a specific therapy is working or not. He further added, Biomarkers are an attractive part of cancer therapy, and novel agents & drugs are prescribed based on a specific target population after understanding the mutation as well as the response rate, which is anticipated to create huge opportunities for the growth of cancer biomarkers industry. quote

Mohd. Adnan Malik
Analyst - Healthcare Research at Allied Market Research.

Get 20% Free Customization In This Report
Follow us on Social Media:       

Cancer Biomarkers Market Report, published by Allied Market Research, forecasts that the global market is projected to reach $15,737 million by 2022 from $6,521 in 2015, growing at a CAGR of 13% from 2016 to 2022. Omic technologies segment accounted for more than half of the revenue share in 2015 and is expected to maintain its dominance during the forecast period. Europe and Asia-Pacific together accounted for more than half of the market share in 2015.

Read full summary of the report at:

The market for cancer biomarkers is primarily driven by rise in prevalence of cancer cases, growing importance of biological & targeted drug therapies, technological advancements, and accuracy & reliability of cancer biomarkers for cancer detection. Moreover, rise in investments from government, public & private sector for biomarker research and technological advancements for cancer diagnostics have a positive impact on the market. However, high cost of drug development, threat of failure, and unregulated government regulations & reimbursement policies could restrain the market. Yet, the impact of these limitations is anticipated to reduce due to substantial surge in cancer diagnosis as well as increased focus towards advanced treatment protocols.

In terms of applications, diagnostics accounted for major share of the global cancer biomarkers market in 2015, and is projected to maintain this trend throughout the forecast period growing at a CAGR of 14%.

In terms of profiling technology, omic technology is the most popular and conventional method for biomarker detection and is projected to grow at a CAGR of 12%. However, immunoassays segment is anticipated to experience higher adoption rate, majorly due to the increase in use of flow cytometry, and is expected to grow at a CAGR of 18% during the forecast period.

In the year 2015, genetic biomarkers accounted for highest revenue share and is expected to grow at a CAGR of 13% during the forecast period. The use of genetic biomarkers for detecting gene mutations and gene expressions is expected to drive the growth of the biomolecule. However, use of glyco biomarkers due to better identification of cancerous gene is further expected to increase the segment growth which is expected to grow by 14% during the forecast period.

Key Findings of the Cancer Biomarkers Market:

  • Immunoassays are projected to be the fastest growing segment, growing at a CAGR of 18% during the forecast period.
  • Omic technologies is anticipated to be the highest revenue generating segment followed by imaging technologies during 20162022.
  • In the year 2015, genetic biomarkers was the leading segment and is projected to grow at a CAGR of 13%.
  • Use of protein biomarkers was highest in North America, covering approximately 37% of the global market share in 2015.
  • Europe accounted for approximately one-third of the global cancer biomarkers market in 2015.
  • Asia-Pacific is estimated to be the fastest growing region in cancer biomarkers market, growing at a CAGR of 14%.
  • Mexico is projected to be the fastest growing country in the North America region growing at a CAGR of 13% during the forecast period.
  • China and Japan were the leading markets for cancer biomarkers in the Asia-Pacific region covering three-fifth of the total market in 2015.

North America dominated the global cancer biomarkers market. This is primarily attributed to the biomarker discoveries resulting from technological advancements. Moreover, rise in awareness about cancer as well as availability of better treatment facilities has also fueled the market growth. Europe and Asia-Pacific together accounted for around half of the market in 2015.

The companies adopted collaboration and partnership as their prime strategy to keep pace with the changing demands of consumers and strengthen their market position. The key players for this market include F.Hoffmann-La Roche Ltd., Abbott Laboratories, GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Inc., Qiagen N.V. and Genomic Health, Inc.

Need More Information

pr-det-talk Talk to David (Europe)

pr-det-talk Talk to Sona Padman (Americas)

5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States

pr-det-phone Toll Free: +1-800-792-5285

pr-det-phone UK: +44-845-528-1300

pr-det-phone Hong Kong: +852-301-84916

pr-det-phone India (Pune): +91 2066346060

pr-det-phone Fax: +1(855) 550-5975

pr-det-phone help@alliedmarketresearch.com


For Media Inquiries, Please Contact

Shaun Godinho
Communications Officer
Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at


First time buyer?
Check offers and discount on this report
To get this report

Click Here

quote Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecules (Genetic Biomarkers, Protein Biomarkers, Glycoprotein Biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer), Application (Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment) - Global Opportunity Analysis and Industry Forecast, 2014 - 2022 quote

View Report

Why Allied Market Research?


Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time of readers


Featured Readings


Get Fresh content delivered

Get insights on topics that matter to your business. Stay updated on the area that interests you.

Get Industry Data Alerts

Buy Full Version
"Cancer Biomarkers Market"
Purchase Enquiry